Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Alfentanil→

Alfentanil Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
71195-58-9
Molecular formula
C21H32N6O3
Molecular weight
416.5 g/mol
Drug class
Potent synthetic opioid analgesicshort-acting mu-opioid receptor agonist
Mechanism of action
Activates opioid receptors, particularly mu-opioid receptors, reducing nociceptive neurotransmission and producing analgesia and dose-dependent respiratory and central nervous system depression.
Indications / reported uses
  • Adjunct to general anaesthesia for analgesia during short surgical procedures
  • Analgesic component of monitored anaesthesia care and selected procedural sedation/anaesthesia settings under specialist monitoring; formulation and national product label apply

Sources: UK product information — Alfentanil injection · NLM MeSH — Alfentanil · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Alfentanil Environmental Risk Assessment (ERA) (the Alfentanil ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.